Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US

Delivers Global First With Ranibizumab Biosimilar Launch Through Partner Biogen

Executive Summary

Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.

You may also be interested in...



Samsung Bioepis Responds To Rumor Of Biogen Biosimilars Buyout

Rumors of another major biosimilars deal are spreading after Korean media reported that Samsung Bioepis could be considering a bid for Biogen’s biosimilars business.

Xbrane Gets Action Date As Ranibizumab Filing Accepted By FDA

Xbrane has announced the formal acceptance by the US FDA of its re-filed ranibizumab biosimilar, developed in collaboration with Stada and licensed in North America to Bausch + Lomb.

Biogen Is ‘Evaluating Strategic Options’ For Its Biosimilars Business

Biogen revealed that a formal process is now underway to “evaluate strategic options” for its biosimilars business, pointing to a potential transfer of the unit to a new owner.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel